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MetastasisSummary The objective of this study is to correlate the expression of epidermal growth factor receptor
(EGFR) components with clinical behavior of early-stage cervical cancer. Tissue samples of 336
consecutive Federation of International Gynecologists and Obstetricians stage IB-IIA cervical cancer
patients all treated primarily by radical surgery were collected. Clinicopathologic and follow-up data
were prospectively obtained during standard treatment and follow-up. As representatives for the EGFR
pathway, expression of EGFR, pEGFR, PTEN, pAKT, and pERK was assessed by immunohistochem-
istry on tissue microarrays. Positive immunostaining was observed for EGFR in 32.1%, for pEGFR in
21.0%, for PTEN in 38.3%, for pAKT in 5.3%, and for pERK in 4.3% of tumor samples. Positive EGFR
immunostaining was associated with squamous cell carcinoma of the cervix (odds ratio [OR], 7.41; 95%
confidence interval [CI], 3.38-16.23, P b .001), negative pEGFR immunostaining with poor
differentiation (OR, 0.39; 95% CI, 0.20-0.73, P = .004), and negative PTEN immunostaining with
metastatic pelvic lymph nodes (OR, 0.51; 95% CI, 0.30-0.90, P = .019). In multivariate analysis, only
pelvic lymph node metastasis (hazard ratio, 6.11; 95% CI, 3.46-10.77, P b .001) and poor
differentiation (hazard ratio, 1.91; 95% CI, 1.12-3.26, P = .018) were related to disease-specific
survival. In early-stage cervical cancer, loss of PTEN expression is associated with pelvic lymph node
metastasis, suggesting PTEN to be one of the tumor suppressor genes affecting pelvic lymph node
metastasis. However, expression of EGFR pathway components does not appear to have prognostic
impact in surgically treated early-stage cervical cancer.
© 2010 Elsevier Inc. All rights reserved.⁎ Corresponding author.
E-mail address: a.g.j.van.der.zee@og.umcg.nl (A. G. J. van der Zee).
046-8177/$ – see front matter © 2010 Elsevier Inc. All rights reserved.
oi:10.1016/j.humpath.2010.04.017
1736 J. J. H. Eijsink et al.1. Introduction prospectively entered into a computerized database. ClinicalEarly-stage cervical cancer is generally treated by radical
hysterectomy and pelvic lymph node dissection. In cases
with poor clinicopathologic factors, adjuvant radiotherapy
with or without chemotherapy is often administered.
Conventional prognostic factors in early-stage cervical
cancer are tumor size, depth of stromal invasion, lympho-
vascular space involvement, parametrial invasion, and pelvic
lymph node metastasis [1-4]. Pelvic lymph node metastasis
appears to be the most important of these parameters [5],
with a 5-year survival approximating 90% in node-negative
early-stage cervical cancer patients primarily treated with
surgery and decreasing to approximately 65% in patients
with pelvic lymph node metastasis [6]. In early-stage cervical
cancer, molecular markers could be helpful in selecting
lymph node–negative patients with an unfavorable prognosis
for adjuvant treatment and might identify new targets for
patient-tailored therapy.
The epidermal growth factor receptor (EGFR) is involved
in the ErbB signaling network, which is often deregulated in
cancer. Autophosphorylation of EGFR to pEGFR leads to
activation of the Ras/Raf/MEK/ERK pathway and the
phosphoinositide 3-kinase (PI3K)/AKT pathway, both of
which are involved in processes that are associated with
carcinogenesis and tumor progression, such as inhibition of
apoptosis, cell migration, cell growth, and angiogenesis [7].
PTEN (phosphatase and tensin homolog deleted on chro-
mosome 10) acts as a tumor suppressor gene by inhibiting
phosphorylation and thereby activation of AKT [8,9]. Only
few data, obtained in small series of cervical cancer patients
primarily treated by surgery, exist on EGFR or PTEN
expression [10-13], and no published studies provide a
comprehensive analysis of several EGFR pathway compo-
nents simultaneously in a well-defined series of early-stage
cervical cancer patients.
Previous studies of molecular markers in early-stage
cervical cancer have been limited by the small number of
patients evaluated and/or mediocre documentation of
clinicopathologic parameters. The present study was
designed to correlate expression of EGFR, pEGFR, PTEN,
pAKT, and pERK in relation to clinicopathologic parameters
and disease-specific survival in a large, well-documented
series of patients with early-stage cervical cancer and long-
term follow-up.2. Materials and methods
2.1. Patients and treatment
Since 1980, clinicopathologic characteristics and follow-
up data of all cervical cancer patients referred to the
Department of Gynaecologic Oncology of the University
Medical Center Groningen, the Netherlands, have beenstaging of each patient is performed under general
anesthesia in accordance with the Federation of International
Gynecologists and Obstetricians (FIGO) criteria. For the
present study, we selected all early-stage cervical cancer
patients, treated primarily by surgery between January 1980
and December 2004 from our database (n = 336). All
patients underwent type 3 radical hysterectomy and pelvic
lymph node dissection. Patients with pelvic lymph node
metastases, parametrial invasion, or positive excision
margins received adjuvant external beam radiotherapy
with or without chemotherapy. Paraffin-embedded forma-
lin-fixed primary tumor tissue was collected from each
patient. Patients were only included in our analysis if
sufficient representative tumor tissue was available for tissue
microarray (TMA) construction. After completion of
treatment, patients were followed up at the outpatient clinic
for at least 5 years.
2.2. Institutional review board approval
In the University Medical Center Groningen, clinicopath-
ologic and follow-up data are prospectively obtained during
standard treatment and follow-up and stored in a computer-
ized registration database. For the present study, all relevant
data were retrieved from this computerized database into a
separate, anonymous database. Patient identity was protected
by study-specific, unique patient numbers. Codes were only
known to 2 dedicated data managers, who also have daily
responsibility for the larger database. In case of uncertainties
with respect to clinicopathologic and follow-up data, the
larger databases could only be checked through the data
managers, thereby ascertaining the protection of patients'
identity. Using the registration database, we identified all
tissue specimens by unique patient numbers and retrieved
them from the archives of the Department of Pathology.
Therefore, according to Dutch law, no further Institutional
Review Board approval was needed for this study (http://
www.federa.org/).
2.3. Tissue microarray construction
As previously described, representative areas of tumor
were marked on hematoxylin and eosin–stained slides of the
paraffin-embedded tissue [14]. Areas of necrosis and/or
heavy leukocytic infiltrate were avoided. The TMAs were
constructed using a precision instrument (Beecher Instru-
ments, Silver Spring, MD). Three 0.6 mm in diameter cores
were punched from themarked area of the paraffin-embedded
tissue (donor block) and transferred to a predefined location
in a blank paraffin block (recipient block). After all the cores
had been inserted, the recipient block was placed in an oven
of 37°C for 15 minutes to attach the cores to the surrounding
paraffin. Each TMA also contained benign (skin epithelia,
normal cervical tissue, and colon polyps) and tumor (breast,
colon and ovarian carcinoma) tissue that served as controls
1737Expression of EGFR components in early-stage cervical cancerfor immunostaining and comparison of TMAs. In total, 5
TMAs were constructed.
2.4. Immunohistochemistry
For immunohistochemistry, 4-μm sections were cut from
the TMA and mounted on amino-propyl-ethoxy-silan
(Sigma-Aldrich, Diessenhofen, Germany)–coated glass
slides. Immunohistochemistry for EGFR, pEGFR, PTEN,
pAKT, and pERK was performed as described previously
[15]. Details of the antibodies used for immunohistochem-
istry and methods for antigen retrieval are summarized in
Table 1. The avidin-biotin-peroxidase method was used for
all antibody detection, except pAKT for which the EnVision
horseradish peroxidase system (Dako, Copenhagen,
Denmark) was used. Slides were deparaffinized in xylene
and rehydrated in ethanol. Endogenous peroxidase was
blocked by incubation with 0.3% hydrogen peroxidase for
30 minutes. For staining in which the avidin-biotin-
peroxidase method was used, endogenous avidin and biotin
activity was blocked using a blocking kit (Vector Laborato-
ries, Burlingame, UK). Immunostaining was visualized by 3′
3-diaminobenzidine tetrahydrochloride, and counter immu-
nostaining was performed with hematoxylin.
2.5. Evaluation of immunostaining
Scoring was performed by 2 independent observers (JJHE
and MGN) without knowledge of clinical data. A concor-
dance of more than 90% was found. The discordant cases
were reviewed, and scores were reassigned on consensus.
Immunostaining intensity was semiquantitatively scored.
Only patients with at least 2 representative cores were
included in the analysis. Tumors were considered positive for
EGFR when more than 10% positive membranous immu-
nostaining was observed [12]. pAKT and pERK immunos-
taining were considered positive if more than 10% of a tumor
showed cytoplasmic and/or nuclear immunostaining [15].
Positive expression of PTEN was defined as more than 10%
cytoplasmic immunostaining [16]. Positive pEGFR was
defined as at least weak positive cytoplasmic immunostain-
ing, as the activated EGFR is internalized [17].Table 1 Antibodies used for immunostaining
Antigen Antigen retrieval Clone
PTEN Citrate (pH 6) a 6H2.1
EGFR Proteinase K 0.1%, 30 min 111.6
pEGFR EDTA (pH 8) a 1H12
pAKT 1/2 Citrate (pH 6) a 736E11
pERK 1/2 Citrate (pH 6) a 20G11
a Sections were boiled in a microwave for 15 minutes.
b Cascade Bioscience, Winchester, MA.
c Neomarkers, Lab Vision Corporation, Fremont, CA.
d Cell Signaling, Danvers, MA.2.6. Statistical analysis
Statistical analysis was performed with SPSS 16.0 for
Windows (SPSS Inc, Chicago, IL). Associations (odds ratios
[ORs] and 95% confidence interval [CI]) between immu-
nostaining intensity and clinicopathologic characteristics
were assessed in a univariate logistic regression model using
positive protein expression as dependent factor and the
clinicopathologic characteristics as independent factors.
Relations (hazard ratios [HR] and 95% CI) between
disease-specific survival, clinicopathologic features, and
immunostaining were calculated using both univariate and
multivariate Cox proportional hazard analysis. In these
analyses, factors with a P value greater than .10 in the
univariate analyses were excluded stepwise in multivariate
analyses. P values of less than .05 were considered
statistically significant.3. Results
3.1. Patients and tumor characteristics
In total, 336 patients diagnosed with early-stage cervical
cancer (IB1: n = 221 [66%]; IB2: n = 63 [19%]; IIA: n = 52
[15%]) and treated by radical hysterectomy and pelvic lymph
node dissection were identified. In 310 cases, sufficient
pretreatment tissue was available for TMA construction.
Median age was 43 years (range, 17-86 years), and median
follow-up time was 5.5 years (range, 0.31-18.60 years).
Overall, 5-year disease-specific survival for the 310 patients
was 82.4%. Additional patient and tumor characteristics are
summarized in Table 2.
3.2. Clinicopathologic factors in relation to EGFR,
pEGFR, PTEN, pAKT, and pERK
The proportion of patients included in the analysis based
on 2 or more representative cores was 93.5% for EGFR,
93.5% for pEGFR, 91.0% for PTEN, 90.7% for pAKT, and
89.1% for pERK. Fig. 1 shows a representative negative andCompany Dilution Incubation time
Cascade b 1:100 60 min
Neomarkers c 1:200 60 min
Cell Signaling d 1:200 60 min
Cell Signaling d 1:50 Overnight (4°C)
Cell Signaling d 1:50 Overnight (4°C)









WM + radiotherapy 106 (34%)
WM + chemoradiotherapy 16 (5%)
Tumor type












0-10 mm 165 (53%)









0-4 cm 223 (72%)







Abbreviation: WM = Wertheim-Meigs.
Fig. 1 Tumor microarray stained for EGFR, pEGFR, PTEN,
pAKT, and pERK (100×). Negative staining (A, C, E, G, and I).
Positive staining (B, D, F, H, and J).
1738 J. J. H. Eijsink et al.positive core for each staining. Positive EGFR immunostain-
ing was observed in 93 (32.1%) of 290 patients, positive
pEGFR immunostaining in 61 of 290 (21.0%) patients,
positive PTEN immunostaining in 108 (38.3%) of 282
patients, positive pAKT immunostaining in 15 (5.3%) of 281
patients, and positive pERK immunostaining in 12 (4.3%) of
276 patients. Positive pEGFR immunostaining correlated
with PTEN (OR, 2.454; 95% CI, 1.367-4403, P = .003) and
with pERK (OR, 4.468; 95% CI, 1.380-14.468, P = .013).
No additional correlations between the immunostains were
found (data not shown).
Table 3 shows clinicopathologic features in relation to
immunostaining. Positive membranous immunostaining forEGFR was associated with squamous cell carcinoma of the
cervix (OR, 7.41; 95% CI, 3.38-16.23, P b .001), negative













































































































































































































































































































































































































































































































































1739Expression of EGFR components in early-stage cervical cancerpoor differentiation (OR, 0.39; 95% CI, 0.20-0.73, P = .004),
and negative PTEN immunostaining was associated with
metastatic pelvic lymph nodes (OR, 0.51; 95% CI, 0.30-0.90,
P = .019).
3.3. EGFR, pEGFR, PTEN, pAKT, and pERK and
disease-specific survival
In univariate Cox regression analysis, none of the
immunostain results correlated with disease-specific survival
(Table 4). In multivariate Cox regression analysis, only
positive lymph nodes (HR, 6.11; 95% CI, 3.46-10.77, P b
.001) and poor differentiation (HR, 1.91; 95% CI, 1.12-3.26,
P = .018) were independent prognostic factors for disease-
specific survival.4. Discussion
Immunohistochemical expression of EGFR pathway
components EGFR, pEGFR, PTEN, pAKT, and pERK was
evaluated in relation to clinicopathologic parameters and
disease-specific survival in a consecutive series of early-
stage cervical cancer patients. Our study indicates that loss of
PTEN expression frequently occurs in early-stage cervical
cancer and is related to pelvic lymph node metastasis (OR,
0.51; 95% CI, 0.30-0.90, P = .019), but not to survival. Only
limited data exist on PTEN expression and its possible
implications for the biologic behavior of cervical cancer. In a
study by Lee et al [13], reduced PTEN expression was
identified in 17.6% (15/85) of surgically treated cervical
cancer patients and was associated with decreased disease-
free and overall survival, but not with pelvic lymph node
metastasis. They reported a gradual reduction of PTEN
expression along the continuum from normal epithelium
through intraepithelial neoplasia to squamous cell carcino-
ma. Discrepancies between the data from Lee et al [13] and
our study might be due to the number of evaluated patients
(n = 85 vs n = 310) and/or interpretation of immunostaining,
because Lee et al defined reduced PTEN expression by
comparison with corresponding normal tissue. In our
opinion, a minimal percentage of positive cells should be
taken into account when assessing PTEN expression in a
tumor. In a study comparing different immunostaining in
TMA and full sections of vulvar cancer patients, a minimal
percentage of positive cells was also taken into account, and
this study resulted in a good reproducibility of immunostain-
ing on TMA [18].
Experimental data also indicate a role for loss of PTEN in
determining the metastatic potential of tumors. In a study
using a benign melanocytic hyperplasia mice model,
silencing PTEN leads to the development of melanoma and
metastases to lymph nodes and lungs [19]. In a study of
colorectal cancer patients, Sawai et al [20] observed an
association between reduced PTEN expression and liver
Table 4 Disease-specific survival (Cox regression analysis)
Univariate Multivariate
HR (95% CI) P HR (95% CI) P
Age 1.02 1.00-1.04 .055 #
Stage ≥IB2 2.34 1.38-3.98 .002 #
Squamous 0.72 0.40-1.29 .266 #
Poor differentiation 1.73 1.01-2.95 .045 1.91 1.12-3.26 .018
Lymphangioinvasion 2.38 1.32-4.26 .004 #
Infiltration depth ≥10 mm 2.00 1.15-3.49 .014 #
Positive lymph nodes 5.76 3.30-10.04 b.001 6.11 3.46-10.77 b.001
Tumor diameter ≥4 cm 2.45 1.44-4.16 .001 #
EGFR 1.24 0.69-2.22 .468 #
pEGFR 0.81 0.39-1.66 .556 #
PTEN 0.61 0.33-1.14 .120 #
pAKT 0.71 0.17-2.93 .638 #
pERK 0.05 0.0-15.02 .298 #
Abbreviation: # = not included in final analysis.
1740 J. J. H. Eijsink et al.metastases. Activation of receptor tyrosine kinases such as
epidermal growth factor receptor, Her2/neu, and insulin-like
growth factor receptor 1 results in recruitment of PI3K [9].
The direct product of PI3K is phosphatidylinositol-3,4,5-
triphosphate (PIP3), and PIP3 is the primary target of PTEN
[21]. Loss of PTEN function results in accumulation of PIP3
and thereby deletes activation of its downstream targets, the
AKT pathway. Activation of the AKT pathway may cause
cell cycle progression, cell survival, cell spreading and
motility, and angiogenesis [9]. In our study, no relation
between loss of PTEN and activation of the AKT pathway
was found. Our low percentage (5.3%) of pAKT-positive
cases is in contrast to previous studies in cervical cancer that
used the same antibody and staining protocol but observed
29% to 94% pAKT-positive cases [22-24]. A major
difference between these studies and our study is that we
assessed pAKT in a much larges series (310 vs 31) of early-
stage cervical cancer patients.
Loss of PTEN can be due to mutations, deletions, gene
promoter methylation, or microRNAs (miRs) [25-28].
Mutations and deletions of PTEN are rare events in cervical
cancer [16,22,29]. In a study by Yang et al, PTEN
methylation was observed in 20 (15.7%) of 127 cervical
cancers, whereas Cheung et al [16] reported PTEN
methylation in 36 (58%) of 62 of squamous cell cervical
cancers. They found no PTEN expression in 3 of 10 PTEN
methylation–negative cases and in 0 of 10 PTEN methyla-
tion–positive cases. Preliminary data from our cases show
PTEN gene promoter methylation in 4 (21%) of 19 cases.
No PTEN immunostaining was observed in these 4 PTEN
methylation–positive cases (data not shown). Loss of PTEN
expression could also occur via miRs. Several miRs, such as
miR-21 and miR-214, can target PTEN [27,28]. Both miRs
appear to be up-regulated in cervical cancer [30,31], but a
relation with PTEN loss has not been reported. It might be
that loss of PTEN expression can only partially be explained
by down-regulation via miRs.A downstream component of the PI3K/AKT pathway,
known as the mammalian target of rapamycin (mTOR)
pathway, is up-regulated in many cancers. As a consequence
of PTEN loss, activation of the mTOR pathway may occur.
As shown in in vitro and in vivo experiments, cells without
PTEN are more sensitive to mTOR inhibitors (rapamycin)
[32,33]. These mTOR inhibitors might provide efficacious
additional therapy in cervical cancer patients with an
unfavorable prognosis and loss of PTEN.
Our study indicates a strong relation between squamous
cell carcinomas and EGFR staining, which was previously
reported in cervical cancer by Kersemaekers et al [11]. In
their study, EGFR overexpression was observed in 54% (73/
136) cervical cancer cases and was associated with reduced
disease-free and reduced overall survival in surgically
treated cervical cancer patients [11]. These findings could
not be confirmed in our large series of cervical cancer
patients, where 32.1% of cases overexpressed EGFR. One
explanation might be the use of a different antibody.
Another possibility is that our study included a larger
percentage of adenocarcinomas (28% vs 9%), and as is
shown in our study, EGFR expression is highly associated
with squamous cell carcinoma.
In conclusion, in early-stage cervical cancer, loss of
PTEN expression is associated with pelvic lymph node
metastasis, suggesting that PTEN is one of the tumor
suppressor genes affecting pelvic lymph node metastasis in
early-stage cervical cancer. Overall, however, the EGFR
pathway does not appear to have prognostic impact in
surgically treated early-stage cervical cancer.
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